CA2526175A1 - Medicament for internal application, in particular against cancerous diseases - Google Patents
Medicament for internal application, in particular against cancerous diseases Download PDFInfo
- Publication number
- CA2526175A1 CA2526175A1 CA002526175A CA2526175A CA2526175A1 CA 2526175 A1 CA2526175 A1 CA 2526175A1 CA 002526175 A CA002526175 A CA 002526175A CA 2526175 A CA2526175 A CA 2526175A CA 2526175 A1 CA2526175 A1 CA 2526175A1
- Authority
- CA
- Canada
- Prior art keywords
- specifically
- surfactants
- drug
- polydimethylsiloxane
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 16
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 16
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 8
- 229910021536 Zeolite Inorganic materials 0.000 claims description 7
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 7
- 239000010457 zeolite Substances 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 6
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 6
- 235000012211 aluminium silicate Nutrition 0.000 claims description 6
- 239000003945 anionic surfactant Substances 0.000 claims description 6
- 239000010459 dolomite Substances 0.000 claims description 6
- 229910000514 dolomite Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002280 amphoteric surfactant Substances 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008527 organismal homeostasis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011034 rock crystal Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323758A DE10323758A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| DE10323758.5 | 2003-05-22 | ||
| PCT/DE2004/001048 WO2004105776A1 (de) | 2003-05-22 | 2004-05-19 | Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2526175A1 true CA2526175A1 (en) | 2004-12-09 |
Family
ID=33441299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002526175A Abandoned CA2526175A1 (en) | 2003-05-22 | 2004-05-19 | Medicament for internal application, in particular against cancerous diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070172435A1 (enExample) |
| EP (1) | EP1635849A1 (enExample) |
| JP (1) | JP2006528211A (enExample) |
| CN (1) | CN1795001A (enExample) |
| AU (1) | AU2004243524A1 (enExample) |
| CA (1) | CA2526175A1 (enExample) |
| DE (1) | DE10323758A1 (enExample) |
| RU (1) | RU2005140097A (enExample) |
| WO (1) | WO2004105776A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10323759A1 (de) * | 2003-05-22 | 2004-12-16 | Bauer, Wulf, Dr. | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| BE1018537A3 (fr) | 2007-09-13 | 2011-03-01 | Basf Se | Procede d'exploitation d'une separation en continu d'un produit cible x sous la forme d'un cristallisat finement divise. |
| DE102007043748A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102007043758A1 (de) | 2007-09-13 | 2008-10-23 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat des Zielproduktes X |
| DE102007043759A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102010030279A1 (de) | 2010-06-18 | 2010-10-28 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
| US8461383B2 (en) | 2009-10-16 | 2013-06-11 | Basf Se | Process for starting up a separating process for purifying removal of acrylic acid crystals from a suspension S of crystals thereof in mother liquor |
| DE102009045767A1 (de) | 2009-10-16 | 2010-08-12 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
| US10398727B2 (en) | 2014-11-24 | 2019-09-03 | University Of Technology, Sydney | Methods for the treatment and prevention of asbestos-related diseases |
| CN104606261B (zh) * | 2015-03-05 | 2018-02-09 | 潘友长 | 一种沸石药物组合物及其制备方法和用途 |
| CN105837734A (zh) * | 2016-05-09 | 2016-08-10 | 上海惠昌化工厂 | 有机硅改性丙烯酸聚酯钾盐及制备方法和防癌治癌用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310572A (en) * | 1987-02-03 | 1994-05-10 | Dow Corning Corporation | Process for forming a coated active agent-containing article |
| US5418220A (en) * | 1994-03-08 | 1995-05-23 | Schmidt; Alfred | Method for treating constipation using dimethicone |
| US5587149A (en) * | 1995-02-06 | 1996-12-24 | R.P. Scherer Corporation | Topical application emulsions |
| DE59707063D1 (de) * | 1996-03-25 | 2002-05-23 | Bauer Wulf | Heilmittel zur äusserlichen anwendung und verwendung einer wässrigen öl-emulsion für ein derartiges heilmittel |
| US6347408B1 (en) * | 1998-11-05 | 2002-02-19 | Allegiance Corporation | Powder-free gloves having a coating containing cross-linked polyurethane and silicone and method of making the same |
| EP1107826A1 (de) * | 1999-04-26 | 2001-06-20 | Tihomir Lelas | Vorrichtung zum mikronisieren von materialien |
-
2003
- 2003-05-22 DE DE10323758A patent/DE10323758A1/de not_active Withdrawn
-
2004
- 2004-05-19 EP EP04733761A patent/EP1635849A1/de not_active Withdrawn
- 2004-05-19 RU RU2005140097/15A patent/RU2005140097A/ru unknown
- 2004-05-19 JP JP2006529603A patent/JP2006528211A/ja not_active Withdrawn
- 2004-05-19 WO PCT/DE2004/001048 patent/WO2004105776A1/de not_active Ceased
- 2004-05-19 US US10/557,317 patent/US20070172435A1/en not_active Abandoned
- 2004-05-19 CA CA002526175A patent/CA2526175A1/en not_active Abandoned
- 2004-05-19 CN CNA2004800140406A patent/CN1795001A/zh active Pending
- 2004-05-19 AU AU2004243524A patent/AU2004243524A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1635849A1 (de) | 2006-03-22 |
| WO2004105776A1 (de) | 2004-12-09 |
| CN1795001A (zh) | 2006-06-28 |
| AU2004243524A1 (en) | 2004-12-09 |
| RU2005140097A (ru) | 2006-08-10 |
| JP2006528211A (ja) | 2006-12-14 |
| US20070172435A1 (en) | 2007-07-26 |
| DE10323758A1 (de) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mendiratta et al. | Multidisciplinary role of mesoporous silica nanoparticles in brain regeneration and cancers: From crossing the blood–brain barrier to treatment | |
| CA2526175A1 (en) | Medicament for internal application, in particular against cancerous diseases | |
| JP2009506076A5 (enExample) | ||
| US20230001128A1 (en) | Aerosolization systems, methods, and apparatuses | |
| TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
| CA2298093A1 (en) | An anti-cancer therapy agent of arsenic hexoxide (as4o6) of a natural chemical substance and its pharmaceutical composition | |
| WO2019021769A1 (ja) | 薬剤及びその製造方法 | |
| NZ541745A (en) | (spiro[8-azaniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-4[hydroxydiphenylacetyl)oxy]chloride (1a, 3b, 5a)) containing compositions | |
| US20060251738A1 (en) | Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases | |
| JP2006528210A5 (enExample) | ||
| JP2006528211A5 (enExample) | ||
| Hodgson et al. | Saunders Nursing Drug Handbook 2013 | |
| DE50200711D1 (de) | Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden | |
| ES2729716T3 (es) | Mineral de arcilla para la reducción de fosfatos inorgánicos, en particular en el contexto de una terapia de sustitución renal | |
| EA200971113A1 (ru) | Шипучие таблетки для ингаляционного применения | |
| Zhang et al. | Protective effect of nanoparticles from platycladi cacumen carbonisata on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats | |
| JP6125634B2 (ja) | 薬用粘土製剤 | |
| Keshtiara et al. | Ruthenium (III)–Indigo Complex Loaded on the Salep Hydrogel as an Anti-inflammatory and Antioxidant Nanocomposite | |
| CN106860476A (zh) | 一种新的药物制剂胶体酒石酸铋颗粒 | |
| CN110571652A (zh) | 一种合成生态负离子h2o-的方法及其装置及应用 | |
| US20240091376A1 (en) | Alzheimer's disease treatment and methods | |
| CN1227744A (zh) | 治疗胃肠道疾病的药物 | |
| CN116981639A (zh) | 一种包含鞣花酸的富勒烯纳米颗粒组合物 | |
| Tan | Augumenting the anticancer properties of l-phenylalanine functionalized nanoscopic porous amino acid mimics (Nano-pPAAMs) | |
| CN118717816A (zh) | 一种具有硅藻的雾化液及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |